Related references
Note: Only part of the references are listed.Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study
Selcuk Gormez et al.
JOURNAL OF HUMAN HYPERTENSION (2021)
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19
Reinhold Kreutz et al.
CARDIOVASCULAR RESEARCH (2020)
Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors
Xian Zhou et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2020)
Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019
Sara Tedeschi et al.
CLINICAL INFECTIOUS DISEASES (2020)
Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)-Related Outcomes in Korea: A Nationwide Population-based Cohort Study
Sun-Young Jung et al.
CLINICAL INFECTIOUS DISEASES (2020)
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
Bo Li et al.
CLINICAL RESEARCH IN CARDIOLOGY (2020)
Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication
Yuchen Chen et al.
DIABETES CARE (2020)
Coronaviruses and the cardiovascular system: acute and long-term implications
Tian-Yuan Xiong et al.
EUROPEAN HEART JOURNAL (2020)
Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19
Nian-Di Tan et al.
GASTROENTEROLOGY (2020)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Biykem Bozkurt et al.
JOURNAL OF CARDIAC FAILURE (2020)
COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
Jianhua Hu et al.
JOURNAL OF INFECTION (2020)
Ramipril in High-Risk Patients With COVID-19
Ignacio J. Amat-Santos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
Francisco J. de Abajo et al.
LANCET (2020)
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
Neil Mehta et al.
JAMA CARDIOLOGY (2020)
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)
Tao Guo et al.
JAMA CARDIOLOGY (2020)
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
Juyi Li et al.
JAMA CARDIOLOGY (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
Harmony R. Reynolds et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
David J. Bae et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives
Carla Felice et al.
AMERICAN JOURNAL OF HYPERTENSION (2020)
Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Murat Selcuk et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2020)
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
Chao Gao et al.
EUROPEAN HEART JOURNAL (2020)
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Julia Hippisley-Cox et al.
HEART (2020)
Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy
Celestino Sardu et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Jiuyang Xu et al.
FRONTIERS OF MEDICINE (2020)
Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients
Priyank Shah et al.
JOURNAL OF HYPERTENSION (2020)
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome
Katherine W. Lam et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study
Jong-moon Hwang et al.
NEUROLOGICAL SCIENCES (2020)
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
Ranu Baral et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Gianluca Trifiro et al.
DRUG SAFETY (2020)
Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study
Yasushi Matsuzawa et al.
HYPERTENSION RESEARCH (2020)
Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study
Khurram Shahzad Khan et al.
SCOTTISH MEDICAL JOURNAL (2020)
Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients
Chen Chen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population
Jose M. Mostaza et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2020)
COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific brief
[Anonymous]
PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE (2020)
Coronaviruses and the cardiovascular system: acute and long-term implications
Tian-Yuan Xiong et al.
EUROPEAN HEART JOURNAL (2020)
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
Chao Gao et al.
EUROPEAN HEART JOURNAL (2020)
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Juan Meng et al.
EMERGING MICROBES & INFECTIONS (2020)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker
Masato Furuhashi et al.
AMERICAN JOURNAL OF HYPERTENSION (2015)
Closing the Gap between Methodologists and End-Users: R as a Computational Back-End
Byron C. Wallace et al.
JOURNAL OF STATISTICAL SOFTWARE (2012)
Share Paper
